Rapport Therapeutics, Inc. financial data

Symbol
RAPP on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3138% %
Debt-to-equity 5% %
Return On Equity -29% % 41%
Return On Assets -27% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47,661,138 shares 30%
Common Stock, Shares, Outstanding 47,650,216 shares 30%
Entity Public Float $474,516,072 USD
Common Stock, Value, Issued $48,000 USD 33%
Weighted Average Number of Shares Outstanding, Basic 37,931,170 shares 8.8%
Weighted Average Number of Shares Outstanding, Diluted 37,931,170 shares 8.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $81,730,000 USD 43%
General and Administrative Expense $28,381,000 USD 26%
Operating Income (Loss) $110,111,000 USD -39%
Nonoperating Income (Expense) $12,411,000 USD -25%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $17,537,000 USD -101%
Net Income (Loss) Attributable to Parent $97,693,000 USD -36%
Earnings Per Share, Basic 7 USD/shares -42%
Earnings Per Share, Diluted 7 USD/shares -42%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $251,359,000 USD 539%
Cash, Cash Equivalents, and Short-term Investments $513,000,000 USD 60%
Assets, Current $520,659,000 USD 60%
Property, Plant and Equipment, Net $3,116,000 USD -8.6%
Operating Lease, Right-of-Use Asset $10,480,000 USD 552%
Other Assets, Noncurrent $1,068,000 USD 465%
Assets $535,323,000 USD 62%
Accounts Payable, Current $3,235,000 USD 145%
Employee-related Liabilities, Current $5,035,000 USD 56%
Accrued Liabilities, Current $8,599,000 USD 70%
Liabilities, Current $14,316,000 USD 102%
Operating Lease, Liability, Noncurrent $9,390,000 USD 909%
Liabilities $23,706,000 USD 195%
Accumulated Other Comprehensive Income (Loss), Net of Tax $145,000 USD -64%
Retained Earnings (Accumulated Deficit) $201,465,000 USD -94%
Stockholders' Equity Attributable to Parent $511,617,000 USD 58%
Liabilities and Equity $535,323,000 USD 62%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $20,237,000 USD -15%
Net Cash Provided by (Used in) Financing Activities $5,000 USD -100%
Net Cash Provided by (Used in) Investing Activities $21,031,000 USD
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 47,650,216 shares 30%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $799,000 USD -81%
Deferred Tax Assets, Valuation Allowance $30,211,000 USD 130%
Deferred Tax Assets, Gross $30,633,000 USD 120%
Operating Lease, Liability $1,476,000 USD -31%
Depreciation $800,000 USD 0%
Payments to Acquire Property, Plant, and Equipment $291,000 USD -73%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $97,955,000 USD -58%
Lessee, Operating Lease, Liability, to be Paid $1,586,000 USD
Property, Plant and Equipment, Gross $4,834,000 USD 18%
Operating Lease, Liability, Current $2,482,000 USD 245%
Lessee, Operating Lease, Liability, to be Paid, Year Two $766,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $820,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $110,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $3,246,000 USD 141%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $244,000 USD 61%
Share-based Payment Arrangement, Expense $16,372,000 USD 49%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares